Japan Nod Positive For Hemlibra But Shadows Linger

Japan has become the third major market after the US and EU to approve Chugai’s novel antibody Hemlibra (emicizumab) for hemophilia, adding another building block for what the company hopes will become a major international growth driver, but some uncertainties remain.